Table 1.
Baseline characteristics
| Proportion of samples that were antibody-positive* | Proportion of individuals that were antibody-positive at any time* | ||
|---|---|---|---|
| Total | 2516/9488 (26·5%) | 1361/4722 (28·8%) | |
| Sex | |||
| Female | 1895/7089 (26·7%) | 1124/3892 (28·9%) | |
| Male | 424/1545 (27·4%) | 237/828 (28·6%) | |
| Unknown | 197/854 (23·1%) | 0/2 | |
| LTCF role | |||
| Resident | 965/3016 (32·0%) | 484/1434 (33·8%) | |
| Staff member | 1551/6472 (24·0%) | 877/3288 (26·7%) | |
| Region of England | |||
| London | 291/809 (36·0%) | 155/350 (44·3%) | |
| South East | 473/1683 (28·1%) | 259/861 (30·1%) | |
| East | 95/574 (16·6%) | 47/261 (18·0%) | |
| East Midlands | 164/911 (18·0%) | 96/521 (18·4%) | |
| West Midlands | 124/607 (20·4%) | 73/318 (23·0%) | |
| South West | 328/1616 (20·3%) | 184/873 (21·1%) | |
| North West | 297/1042 (28·5%) | 168/538 (31·2%) | |
| North East | 590/1571 (37·6%) | 290/654 (44·3%) | |
| Yorkshire and the Humber | 154/675 (22·8%) | 89/346 (25·7%) | |
| LTCF type | |||
| For-profit chains | 1860/6503 (28·6%) | 966/2989 (32·3%) | |
| Not-for-profit chains | 563/2429 (23·2%) | 320/1326 (24·1%) | |
| Independent | 93/506 (18·4%) | 75/407 (18·4%) | |
| LTCF size | |||
| Small (<50 beds) | 916/3843 (23·8%) | 492/1939 (25·4%) | |
| Medium (50–99 beds) | 1549/5491 (28·2%) | 839/2688 (31·2%) | |
| Large (≥100 beds) | 51/154 (33·1%) | 30/95 (31·6%) | |
| Interval | |||
| June 1–July 31, 2020 | 694/2225 (31·2%) | NA | |
| Aug 1–Sept 30, 2020 | 495/1794 (27·6%) | NA | |
| Oct 1–Nov 30, 2020 | 360/1349 (26·7%) | NA | |
| Dec 1, 2020, to Jan 31, 2021 | 200/1136 (17·6%) | NA | |
| Feb 1–28, 2021 | 221/920 (24·0%) | NA | |
| March 1–April 30, 2021 | 546/2064 (26·5%) | NA | |
LTCF=long-term care facility. NA=not applicable.
*
Based on nucleocapsid antibody detected using Abbott assay.